Oral Mucositis Global Market Report 2025

The oral mucositis market size has grown strongly in recent years. It will grow from $1.51 billion in 2024 to $1.63 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth during the historic period can be attributed to the increase in cancer cases, the rise in chemotherapy and radiation treatments, growing awareness of oral mucositis, increased adoption of supportive care therapies, a higher incidence of head and neck cancers, and the rise in research and development in oncology supportive care.

The oral mucositis market size is expected to see strong growth in the next few years. It will grow to $2.08 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to the rising global incidence of cancer, increasing demand for personalized medicine, a growing focus on palliative care, improved patient awareness and education, greater adoption of over-the-counter oral care products, increasing government and healthcare investments, and the rising prevalence of radiation and chemotherapy treatments. Key trends expected during this period include advancements in low-level laser therapy, the development of novel drug delivery systems, the integration of digital health technologies, the adoption of artificial intelligence in treatment planning, progress in tissue engineering and regenerative therapies, and innovations in smart mouthwashes and oral care products.

The rising prevalence of cancer is expected to drive the expansion of the oral mucositis market in the coming years. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells, which can invade and destroy normal tissues. Several factors contribute to the increasing number of cancer cases, including an aging population, lifestyle changes, environmental exposure, infections, and genetic predisposition. Oral mucositis therapy plays a crucial role in supporting cancer patients by alleviating pain, reducing inflammation, preventing secondary infections, and promoting the faster healing of oral tissues. This ultimately enhances their comfort, nutritional intake, and overall quality of life during chemotherapy or radiation therapy. For example, in May 2024, the National Cancer Institute, a US-based government agency, reported that approximately 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide in 2022. Projections indicate that these figures could rise to 29.9 million new cases and 15.3 million deaths annually by 2040. Consequently, the increasing prevalence of cancer is fueling the growth of the oral mucositis market.

Leading companies in the oral mucositis market are focusing on innovative treatment solutions, such as cryotherapy, to reduce the severity and incidence of the condition by using cold therapy to minimize damage to oral tissues. Cryotherapy is a medical treatment that utilizes extreme cold to freeze and eliminate abnormal or diseased tissue and is commonly used to treat conditions such as warts, tumors, or injuries. For instance, in February 2024, Chemo Mouthpiece LLC, a US-based medical device company, announced that its chemo mouthpiece device received approval from the Food and Drug Administration, a US-based government agency. This intraoral ice pack delivers cryotherapy to the oral cavity of chemotherapy patients, proactively managing and treating oral mucositis, a frequent and painful side effect of cancer treatment.

In July 2022, Solasia Pharma K.K., a Japan-based biotechnology company, acquired the episil oral liquid business from Camurus AB for an undisclosed amount. This acquisition aims to strengthen Solasia Pharma K.K.'s oncology and supportive care portfolio by leveraging Camurus AB’s proprietary drug delivery technologies and innovative treatments. The deal enhances Solasia Pharma K.K.'s ability to develop and commercialize advanced therapeutics for cancer patients. Camurus AB is a Sweden-based company specializing in oral mucositis drugs.

Major players in the oral mucositis market are Merck & Co Inc., Amgen Inc., Mundipharma International Limited, Swedish Orphan Biovitrum, EUSA Pharma, Galera Therapeutics Inc., Enzychem Lifesciences Corporation, Oragenics Inc., Soligenix Inc., Jaguar Health Inc., Monopar Therapeutics Inc., EpicentRx, BrainCool, Cellceutix Corporation, GlycoMira Therapeutics Inc., Innovation Pharmaceuticals Inc., Allander Biotechnologies, Aurora BioScience, Solasia Pharma KK, NeoMedLight, MuReva (Lumitex), Prothex Pharmaceuticals Inc.

North America was the largest region in the oral mucositis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oral mucositis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oral mucositis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Oral mucositis is a condition characterized by inflammation and ulceration of the mucous membranes lining the mouth. It commonly occurs as a side effect of cancer treatments, particularly chemotherapy and radiation therapy, which damage the rapidly dividing cells of the oral mucosa.

The primary indications for oral mucositis include chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. Chemotherapy-induced oral mucositis arises when chemotherapy drugs damage the rapidly dividing cells in the mouth’s lining, leading to painful ulcers and inflammation. Available products come in solid and liquid dosage forms, with treatment options including palifermin, amifostine, chlorhexidine, sucralfate, avasopasem, and dusquetide. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by various end-users, such as hospitals, dental clinics, oncology hospitals, and research institutes.

The oral mucositis market research report is one of a series of new reports that provides oral mucositis market statistics, including the oral mucositis industry's global market size, regional shares, competitors with an oral mucositis market share, detailed oral mucositis market segments, market trends and opportunities, and any further data you may need to thrive in the oral mucositis industry. This oral mucositis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral mucositis market consists of revenues earned by entities by providing services such as low-level laser therapy, nutritional support, and cryotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral mucositis market also includes sales of mouthwashes and rinses, gels, sprays, or films, topical analgesics and anesthetics, and anti-inflammatory agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.